[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Arcellx Inc (ACLX)

Arcellx Inc (ACLX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,729,293
  • Shares Outstanding, K 58,480
  • Annual Sales, $ 22,290 K
  • Annual Income, $ -228,930 K
  • EBIT $ -253 M
  • EBITDA $ -255 M
  • 60-Month Beta 0.25
  • Price/Sales 301.85
  • Price/Cash Flow N/A
  • Price/Book 16.54
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -4.07
  • Most Recent Earnings $-1.01 on 02/26/26
  • Next Earnings Date 05/14/26 [--]
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-1.13
  • Number of Estimates 2
  • High Estimate $-1.05
  • Low Estimate $-1.20
  • Prior Year $-1.13
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
114.60 +0.41%
on 03/30/26
115.13 -0.05%
on 04/27/26
+0.50 (+0.44%)
since 03/27/26
3-Month
63.15 +82.23%
on 02/20/26
115.13 -0.05%
on 04/27/26
+46.56 (+67.96%)
since 01/27/26
52-Week
47.86 +140.43%
on 05/07/25
115.13 -0.05%
on 04/27/26
+51.36 (+80.62%)
since 04/25/25

Most Recent Stories

More News
Rutgers University withdraws invite to a graduation speaker over his criticism of Israel

Rutgers University has canceled a planned graduation speech by business leader Rami Elghandour after students raised concerns about his criticism of Israel on social media

ACLX : 115.07 (+0.03%)
Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the successful completion of its previously announced acquisition of Arcellx, Inc. (Nasdaq: ACLX). Under the terms of the transaction,...

ACLX : 115.07 (+0.03%)
GILD : 130.80 (-0.40%)
Are ACLX, MASI, FONR Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

ACLX : 115.07 (+0.03%)
MASI : 177.20 (-0.63%)
FONR : 18.85 (-0.16%)
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--TALK, UNF, ACLX, and FONR

NEW YORK , March 18, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders...

ACLX : 115.07 (+0.03%)
TALK : 5.18 (-0.19%)
FONR : 18.85 (-0.16%)
UNF : 252.41 (-1.56%)
Are MASI, ACLX, GLDD Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

ACLX : 115.07 (+0.03%)
GLDD : 17.00 (+0.18%)
MASI : 177.20 (-0.63%)
Arcellx Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arcellx, Inc. - ACLX

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Arcellx , Inc....

ACLX : 115.07 (+0.03%)
GILD : 130.80 (-0.40%)
Are ACLX, DBRG, AVO, CVGW Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

ACLX : 115.07 (+0.03%)
AVO : 13.08 (-1.65%)
CVGW : 27.47 (-0.83%)
DBRG : 15.63 (-0.06%)
SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--ACLX, VRE, EHAB, and CECO

NEW YORK , March 4, 2026 /PRNewswire/ -- Class Action Attorney  Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars...

ACLX : 115.07 (+0.03%)
EHAB : 13.79 (+0.15%)
VRE : 18.95 (-0.11%)
CECE : 11.65 (+2.19%)
Are ACLX, VRE, LSF Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

ACLX : 115.07 (+0.03%)
VRE : 18.95 (-0.11%)
LSF : 3.05 (-3.17%)
Gilead Sciences Stock: Is GILD Outperforming the Healthcare Sector?

As Gilead Sciences has outperformed its sector peers recently, analysts remain highly optimistic about the stock’s prospects.

ACLX : 115.07 (+0.03%)
XLV : 143.84 (+0.24%)
MRK : 111.80 (+0.38%)
GILD : 130.80 (-0.40%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Arcellx Inc. is a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx Inc. is based in GAITHERSBURG, Md.

See More

Key Turning Points

3rd Resistance Point 115.28
2nd Resistance Point 115.20
1st Resistance Point 115.14
Last Price 115.07
1st Support Level 115.00
2nd Support Level 114.92
3rd Support Level 114.86

See More

52-Week High 115.13
Last Price 115.07
Fibonacci 61.8% 89.43
Fibonacci 50% 81.50
Fibonacci 38.2% 73.56
52-Week Low 47.86

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.